Clinical Trials Logo
  1. Home
  2. Cancer
  3. NCT01586026
  4. Details
NCT01586026 Clinical Trial

Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters

Cancer Clinical Trial

— DISTAL  

Official title:
A Retrospective Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters

Clinical Trial Details — Status: Enrolling by invitation

Administrative data
NCT number NCT01586026
Other study ID # BAS-11-001
Secondary ID
Status Enrolling by invitation
Phase N/A
First received April 25, 2012
Last updated April 27, 2012
Start date May 2012
Est. completion date October 2012

Study information
Verified date April 2012
Source C. R. Bard
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This study is to compare the rate of adverse events in subjects with maintenance flushes greater than 28 days.

Recruitment information / eligibility
Status Enrolling by invitation
Enrollment 100
Est. completion date October 2012
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Male or female, age = 21 years

- Subject has an implanted Bard port with a distally-valved catheter

- Subject has maintenance port flushes with heparin/heparinized saline or normal saline

- Subject is post infusional cancer therapy (solid tumor or hematologic)

- Subject has signed a HIPAA Authorization to use and disclose PHI

Exclusion Criteria:

- Subject is having port maintenance flushes/locks with citrate.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Locations
Country Name City State
United States St. Luke's Hospital Chesterfield Missouri
United States Southeast Nebraska Cancer Center Lincoln Nebraska
United States Alegent Research Center Omaha Nebraska
United States Quincy Medical Group Quincy Illinois
United States Willis Knighton Cancer Center Shreveport Louisiana

Sponsors (1)
Lead Sponsor Collaborator
C. R. Bard

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary The primary endpoint is to compare the rate of adverse events in Group A (1-28 day flushing interval) versus extended accession intervals in Group B (29-56 day flushing interval), and Group C (57+ days). 100 days Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients